Urinary CTGF in Benign Prostatic Obstruction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: None-placebo.
- Who it may be relevant to
- Registry conditions: Benign Prostatic Hyperplasia, Bladder Outlet Obstruction, Lower Urinary Tract Symptom. Basic parameters: from 40 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Relationship of Urinary CTGF Levels With Bladder Fibrosis and Surgical Treatment Response in Patients With Benign Prostatic Obstruction
Overview
Benign prostatic obstruction (BPO) is one of the most common causes of bladder outlet obstruction (BOO) and may lead to progressive structural and functional alterations in the bladder over time. Prolonged obstruction triggers a bladder remodeling process characterized by detrusor hypertrophy, ischemia-reperfusion injury, smooth muscle loss, and progressive fibrosis. These pathological changes may result in impaired detrusor contractility, increased post-void residual volume, and suboptimal functional recovery following surgical treatment. Connective tissue growth factor (CTGF) is a matricellular protein that plays a key role in fibrogenesis and is markedly upregulated under hypoxic, ischemia-reperfusion, and inflammatory conditions. Experimental and cellular studies have demonstrated that CTGF promotes fibroblast proliferation, extracellular matrix production, and collagen deposition, thereby contributing to bladder fibrosis. Increased CTGF expression has also been associated with fibrotic differentiation of bladder smooth muscle cells. The aim of this observational study is to evaluate the relationship between urinary CTGF levels, bladder fibrosis, and functional response to surgical treatment in patients with benign prostatic obstruction. Preoperative urinary CTGF levels will be assessed and correlated with postoperative functional outcomes and clinical improvement. This study aims to determine whether urinary CTGF may serve as a non-invasive biomarker of bladder fibrosis and a potential predictor of surgical treatment response in patients with BPO.
Interventions
- Other None-placebo
No intervention is assigned as part of this observational study. All diagnostic and surgical procedures are performed as part of routine clinical care.
Primary outcome measures
- Urinary CTGF Level [Time frame: Baseline, measured within 1 week prior to surgical treatment]
Eligibility criteria
Inclusion criteria
Male patients aged > 40 years
- Diagnosis of benign prostatic obstruction (BPO), with or without an indwelling catheter
- Patients with an indication for surgical treatment according to EAU guidelines
Exclusion criteria
- Age < 40 years
- Female sex
- Prostate-specific antigen (PSA) > 2.5 ng/mL
- History of endoscopic urological intervention
- Previous urogenital malignancy or urological surgery
- Diabetes mellitus
- Urethral stricture
- History of pelvic radiotherapy and/or chemotherapy
- Patients performing clean intermittent catheterization
- Neurological diseases causing secondary urinary symptoms (e.g., spinal cord injury, stroke, multiple sclerosis, Parkinson's disease)
- History of spinal surgery
- History of colorectal cancer or previous colorectal surgery
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07416981 · MAR.UAD.0029